Sugi Predict

Sugi Predict / Compounds / SCHEMBL974206

SCHEMBL974206

SCHEMBL974206

CS(=O)(=O)OCCC(O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.47
▸ LMNA P02545 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ AOC3 Q16853 4/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974205 1.00 RIPK1 (0.47) RIPK1LMNAKDM4EL3MBTL1PPARG
SCHEMBL5303572 1.00 RIPK1 (0.47) RIPK1LMNAKDM4EL3MBTL1PPARG
SCHEMBL27911728 0.86 RIPK1 (0.46) RIPK1LMNAKDM4EL3MBTL1AOC3
SCHEMBL3391000 0.84 HRH1 (0.42) LMNAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL2542325 0.82 LMNA (0.48) RIPK1LMNAKDM4EL3MBTL1AOC3
SCHEMBL2541606 0.82 LMNA (0.48) RIPK1LMNAKDM4EL3MBTL1AOC3
SCHEMBL5159743 0.82 LMNA (0.48) RIPK1LMNAKDM4EL3MBTL1AOC3
SCHEMBL10472662 0.81 RIPK1 (0.46) RIPK1LMNAKDM4EAOC3ALDH1A1
SCHEMBL11044391 0.79 MMP13 (0.39) LMNAKDM4EALDH1A1
SCHEMBL9291993 0.79 KMT2A (0.45) RIPK1LMNAKDM4EL3MBTL1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664195-B2 Phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2014-03-04 — — US disclosed
US-20120093729-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2012-04-19 — — US disclosed
US-8080536-B2 Phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2011-12-20 — — US disclosed
US-20110009356-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2011-01-13 — — US disclosed
US-7816345-B2 Phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2010-10-19 — — US disclosed
CN-100494208-C Novel phosphorus-containing prodrug METABASIS THERAPEUTICS INC (US) 2009-06-03 — — CN disclosed
US-20080125605-A1 Novel Phosphorus-Containing Prodrugs METABASIS THERAPEUTICS, INC. 2008-05-29 — — US disclosed
US-7303739-B2 Prodrugs for liver specific drug delivery METABASIS THERAPEUTICS, INC. (US) 2007-12-04 — — US disclosed
US-20070249564-A1 Novel phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2007-10-25 — — US disclosed
CN-101037450-A Novel phosphorus-containing prodrug METABASIS THERAPEUTICS INC (US) 2007-09-19 — — CN disclosed
US-20050101775-A1 Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2005-05-12 — — US disclosed
US-6752981-B1 CYCLIC PHOSPH(ORAMID)ATE PRODRUGS HAVING ALCOHOL, AMINE, ORTHIOL GROUPS ATTACHED TO THE PHOSPHORUS IN THE C3N2P OR C3O2P RING METABASIS THERAPEUTICS, INC. 2004-06-22 — — US disclosed
CN-1353719-A Novel phosphorus-containing prodrugs METABASIS THERAPEUTICS INC (US) 2002-06-12 — — CN disclosed
EP-1210354-A1 PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY Metabasis Therapeutics, Inc. (US) 2002-06-05 — — EP disclosed
EP-1208838-A2 Pure S(+)isomer fluoxetine Sepracor Inc. (US) 2002-05-29 — — EP disclosed
EP-1165570-A2 NOVEL PHOSPHORUS-CONTAINING PRODRUGS Metabasis Therapeutics, Inc. (US) 2002-01-02 — — EP disclosed
WO-2001018013-A1 PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY METABASIS THERAPEUTICS, INC. (US) 2001-03-15 — — WO disclosed
WO-2000052015-A2 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2000-09-08 — — WO disclosed
US-4490165-A Meta-(phenylalkoxy)phenyl-N-methoxy-N-methylurea compounds, methods for preparing same and herbicidal use thereof AMERICAN CYANAMID COMPANY (US) 1984-12-25 — — US disclosed
US-4308213-A Meta-(phenylalkoxy)phenyl-N-methoxy-N-methylurea compounds AMERICAN CYANAMID COMPANY (US) 1981-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125605-A1 Novel Phosphorus-Containing Prodrugs PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885
US-20050101775-A1 Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging PYGL, PHOSPHO1, OAT RIPK1 4800/4885LMNA 3367/4885KDM4E 3585/4885
US-20070249564-A1 Novel phosphorus-containing prodrugs PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885
US-20110009356-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885
US-20120093729-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885KDM4E 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.